Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

